



Making Cancer History®

The goal of this symposium is to provide health care professionals with knowledge and skills resulting in the ability to improve patient care.

EDUCATIONAL OBJECTIVES

After attending the Symposium, participants should be able to

- Implement guidelines to assess and screen high-risk patients in daily practice;
- Recognize and document key features associated with potential hereditary cancer predisposition adequately to refer at-risk patients for cancer assessment;
- Recognize and implement surgical interventions, screening protocols, and systemic therapies appropriate for specific hereditary cancer predisposition syndromes/genes;
- Recognize impact of genetic testing results on the patient, psychosocially and medically, for current and long-term management;
- Identify a genetic counseling service delivery model that fits their clinical practice and implement a referral strategy;
- Differentiate the utility of various genetic testing modalities commonly used related to oncology risk and care.

EDUCATIONAL METHODS

Lectures - Panel Discussions - Case Studies - Question and Answer Sessions

TARGET AUDIENCE

This symposium should be of value to physicians, advanced practice providers, nurses, and oncology genetic counselors.

EVALUATION

A course evaluation survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ETHICS

The "Ethical Considerations for GT" lecture has been designated by The University of Texas MD Anderson Cancer Center for .50 *AMA PRA Category 1 Credits* $^{\text{\tiny ML}}$ in medical ethics and/or professional responsibility.

ACCREDITATION/CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this internet live course for a maximum of 9.50 AMA PRA Category 1 Credits TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates will be provided to participants upon completion of the symposium evaluation.

NURSING

The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of Nursing Continuing Professional Development by The American Nurses Credentialing Center's Commission on Accreditation.

Nursing Certificates will be provided ONLY to participants who complete the online evaluation within the 7 days of the end of the symposium.

The University of Texas MD Anderson Cancer Center designates this internet live course will award 9.75 Nursing Continuing Professional Development (NCPD) credit.

GENETIC COUNSELOR CREDITS

This event will be submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

PROGRAM PLANNING COMMITTEE

Banu Arun, MD, Co-Director *Breast Medical Oncology*

Yoheved "Kevi" Gerstein, MS, CGC, Co-Director Clinical Cancer Genetics

Patti Heitz, MEd, BSN, RN, OCN

Professional Development & Nursing Education

Walter Knowles, MBA Clinical Cancer Genetics

Ann Molinaro, BSBM *Clinical Cancer Genetics*

Julie Moskowitz, MS, CGC Clinical Cancer Genetics Susan Reilly, MS, CGC Clinical Cancer Genetics

Autumn Vara, MS, CGC, Co-Director Clinical Cancer Genetics

Y. Nancy You, MD, MSHc, Co-Director Surgical Oncology

Hiam Abdel-Salam, MS, CGC Clinical Cancer Genetics

Sierra GreenClinical Cancer Genetics

Linda Hill
Clinical Cancer Genetics

Andrew McKeon, MS, CGC Clinical Cancer Genetics

Brad Power, MS, CGCClinical Cancer Genetics

Rachael Shilbauer, MGCS, CGC

Clinical Cancer Genetics

Jacynda Woodman-Ross, MS, CGC

Clinical Cancer Genetics

Felisha Estelle Continuing Professional Education



FRIDAY, APRIL 1, 2022

8:30 am	Introduction and Welcome Banu Arun, MD
8:40	Genetics in Oncology Care Maureen Mork, MS, CGC
9:10	Identifying Red Flags in a Family History Victoria (Tori) McClosky, BSN, RN
9:20	High Risk Screening for Hereditary Cancers Nadine Rayes, MS, CGC
9:55	Live Question & Answer Maureen Mork, MS, CGC; Victoria (Tori) McClosky, BSN, RN; and Nadine Rayes, MS, CGC
10:10	Break
10:20	Treatment Implications of Genetic Testing Results: Systemic Therapy for Breast Cancer Rachel Layman, MD
10:40	Treatment Implications of Genetic Testing Results: Systemic Therapy for Ovarian Cancer Larissa Meyer, MD
11:00	Treatment Implications of Genetic Testing Results: Immunotherapy for Colorectal Cancer Michael Overman, MD
11:20	Live Question & Answer Rachel Layman, MD; Larissa Meyer, MD; and Michael Overman, MD
11:35	Lunch Break
12:20 pm	Identifying Risk Factors for Hereditary Hematologic Malignancy When Taking a Family History Sharon Mattox, APRN
12:35	Overview of Hereditary Hematologic Malignancies Kevi Gerstein, MS, CGC
12:55	Treatment Implications of Genetic Testing Results for Hereditary Hematologic Malignancies Courtney Dinardo, MD
1:25	Live Question & Answer Sharon Mattox, APRN; Kevi Gerstein, MS, CGC; and Courtney Dinardo, MD

1:40	Break
1:50	Hereditary Cancer Implications of Tumor Mutation Profiling Molly Daniels, MS, CGC
2:30	Integrating Universal Germline Genetic Testing into Clinical Practice Donika Saporito, MS, CGC
2:50	Variant Interpretation Jennifer Scull, PhD
3:20	Ethical Considerations for GT Jessica Moore, DHCE, MA
3:50	Live Question & Answer Molly Daniels, MS, CGC; Donika Saporito, MS, CGC; and Jessica Moore, DHCE, MA
4:05	Closing Remarks
4:10 pm	Adjourn
-	-

SATURDAY, APRIL 2, 2022

8:30 am	Welcome Autumn Vara, MS, CGC	
8:40	Genetics in the Pediatric and Young Adult Population Jessica Corredor, MS, CGC	
9:20	Preimplantation Genetic Screening for Hereditary Cancer Sandra Darilek, MS, CGC	
9:50	Break	
10:05	Expert Review Panel of Cases Catherine Skefos, MS, CGC Autumn Vara, MS, CGC Andrew McKeon, MS, CGC	
10:45	Live Question & Answer Jessica Corredor, MS, CGC; Sandra Darilek, MS, CGC; Catherine Skefos, MS, CGC; Autumn Vara, MS, CGC; and Andrew McKeon, MS, CGC	
11:00	Patient Panel Marne Shafer Jason Metts Bryan Joyce	
11:30	Patient Panel Q&A Marne Shafer Jason Metts Bryan Joyce	
11:45	Closing Remarks	
11:50 am	Adjourn	

MD ANDERSON FACULTY

Banu Arun, MD *Breast Medical Oncology*

Jessica Corredor, MS, CGC Clinical Cancer Genetics

Molly Daniels, MS, CGC Clinical Cancer Genetics

Courtney Dinardo, MD Leukemia

Yoheved "Kevi" Gerstein, MS, CGC Clinical Cancer Genetics

Rachel Layman, MD Breast Medical Oncology

Sharon Mattox, APRN Leukemia

Victoria (Tori) McClosky, BSN, RN Breast Center

Andrew McKeon, MS, CGC Clinical Cancer Genetics Larissa Meyer, MD

Gynecologic Oncology and Reproductive Medicine

Jessica Moore, DHCE, MA Sarcoma Medical Oncology

Maureen Mork, MS, CGC Clinical Cancer Genetics

Michael Overman, MD *GI Medical Oncology*

Nadine Rayes, MS, CGC Clinical Cancer Genetics

Donika Saporito, MS, CGC Clinical Cancer Genetics

Catherine Skefos, MS, CGC Clinical Cancer Genetics

Autumn Vara, MS, CGC Clinical Cancer Genetics

GUEST FACULTY

Sandra Darilek, MS, CGC Assistant Professor, Co-Manager Prenatal Genetics Service Molecular & Human Genetic/ Clinical Program Baylor College of Medicine Houston, Texas

Bryan JoycePatient Advocate
New Braunfels, Texas

Jason MettsPatient Advocate
Missouri City, Texas

Marne Shafer *Patient Advocate Katy, Texas*

Jennifer Scull, PhD Assistant Professor, Clinical Director Baylor College of Medicine Baylor Genetic Houston, Texas

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail Continuing Professional Education.

All responses will be forwarded to the Course Directors for consideration.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

REGISTRATION INFORMATION

Conference ID 123732 PFP ID 16325

The 5th Annual Hereditary Cancer Symposium for Healthcare Providers opens at 8:30 a.m. on Friday, April 1, 2022 and ends at 11:50 a.m. on Saturday, April 2, 2022. Advanced registration is encouraged as space and materials are limited. Please see the registration form for applicable fees.

The full symposium registration fee includes the tuition, final program, access to course virtual program.

REGISTRATION FEES	_
Non-MD Anderson Affiliates	
☐ Physicians and Advanced Practice Providers: \$1 ☐ Other HealthCare Professionals (RNs, GCs, etc.): \$ ☐ Non-Clinical, Trainees, Students: \$	75
MD Anderson Affiliates	
☐ Physicians and Advanced Practice Providers: S ☐ Other HealthCare Professionals (RNs, GCs, etc.): S ☐ Non-Clinical, Trainees, Students: S	50

Register on-line at https://mdanderson.cloud-cme.com/Hereditary2022.

We accept the following forms of payment:

- 1. Check (payable through U.S. Banks only)
- 2. Credit cards (Master Card, VISA, and American Express)

A receipt/confirmation letter will be sent to you within ten working days of receipt of your registration.

The Department of Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of Continuing Professional Education is limited to the registration fee. Continuing Professional Education will refund the full registration fee.

The Department of Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

THE UNIVERSITY OF TEXAS
MD ANDERSON CANCER CENTER
CME/CONFERENCE MANAGEMENT, UNIT 1781
176700/30/123732/41
PO BOX 301407
HOUSTON, TEXAS 77230-1407

Non-Profit Org. U.S. Postage P A I D Houston, TX Permit No. 7052